ConductScience.org, home

Paper35967142

The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression.

Pantarotto M and 8 others. Cureus, 2022. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression. Papers, record 35967142. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35967142

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression.
PubMed
Journal
Cureus
PubMed
Year
2022
PubMed
Publication types
Case Reports, Journal Article
PubMed
Citations, by iCite
2
iCite
Relative citation ratio, by iCite
0.3
iCite
Revised in PubMed
2023-02-23
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Pantarotto MMarcos
2Barata RRita
3Coelho RRicardo
4Carvalheiro CCatarina
5Rolim IInes
6Garrido PPatricia
7GIl NNuno
8Duarte-Ramos FFilipa
9Tonin FSFernanda S

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Erratum in36819952Correction: The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression.https://conductscience.org/library/papers/36819952

Source PubMed

Download CSV of comments and corrections

References24

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133598792Sarcoid-like reaction in cases treated by checkpoint inhibitors.Med Oncol2021https://conductscience.org/library/papers/33598792PubMed
230853796Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer.Curr Oncol2019https://conductscience.org/library/papers/30853796PubMed
329763666Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors.J Thorac Oncol2018https://conductscience.org/library/papers/29763666PubMed
429433571Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients.J Immunother Cancer2018https://conductscience.org/library/papers/29433571PubMed
529162153Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.J Immunother Cancer2017https://conductscience.org/library/papers/29162153PubMed
632402357Advances in the Treatment of Stage III Non-Small Cell Lung Cancer.Clin Chest Med2020https://conductscience.org/library/papers/32402357PubMed
733330555Sarcoidosis and Cancer: A Complex Relationship.Front Med (Lausanne)2020https://conductscience.org/library/papers/33330555PubMed
829698718Drug-Induced Sarcoidosis-Like Reactions.Chest2018https://conductscience.org/library/papers/29698718PubMed
934761878Sarcoidosis-like reaction after neoadjuvant pembrolizumab combined with chemotherapy mimicking disease progression of NSCLC induced encouraging discovery of pathological complete response.Thorac Cancer2021https://conductscience.org/library/papers/34761878PubMed
1029898781Thoracic and cutaneous sarcoid-like reaction associated with anti-PD-1 therapy: longitudinal monitoring of PD-1 and PD-L1 expression after stopping treatment.J Immunother Cancer2018https://conductscience.org/library/papers/29898781PubMed
1134855255Development of thoracic sarcoid reactions associated with complete response to anti-PD-1 therapy in a patient with advanced cutaneous squamous cell carcinoma.J Eur Acad Dermatol Venereol2022https://conductscience.org/library/papers/34855255PubMed
1233263945Challenges in sarcoidosis and sarcoid-like reactions associated to immune checkpoint inhibitors: A narrative review apropos of a case.Dermatol Ther2021https://conductscience.org/library/papers/33263945PubMed
1334724392Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.J Clin Oncol2021https://conductscience.org/library/papers/34724392PubMed
1428231584Characteristics of Sarcoidosis in Patients with Previous Malignancy: Causality or Coincidence?Respiration2017https://conductscience.org/library/papers/28231584PubMed
1532099495Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non-Small Cell Lung Cancer: Emerging Mechanisms and Perspectives.Lung Cancer (Auckl)2019https://conductscience.org/library/papers/32099495PubMed
1634452793Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation.Eur J Cancer2021https://conductscience.org/library/papers/34452793PubMed
1734425404Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: A case-control study.Eur J Cancer2021https://conductscience.org/library/papers/34425404PubMed
1830030656The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring.Curr Oncol Rep2018https://conductscience.org/library/papers/30030656PubMed
1932248071Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.Eur J Cancer2020https://conductscience.org/library/papers/32248071PubMed
2033433837Sarcoidosis-like reactions in cancer patients treated with immune checkpoint inhibitors: experience in a Spanish hospital.Clin Transl Oncol2021https://conductscience.org/library/papers/33433837PubMed

See all 24 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
40647656Drug-Induced Sarcoid-like Reactions Associated to Targeted Therapies and Biologic Agents.Diagnostics (Basel)2025https://conductscience.org/library/papers/40647656PubMed
39894895A Unique Case of Poorly Differentiated Neuroendocrine Carcinoma With Brain and Bilateral Adrenal Metastases.Cancer Rep (Hoboken)2025https://conductscience.org/library/papers/39894895PubMed

Download CSV of cited by

Genes11

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35967142

GET https://conductscience.org/api/papers/v1/35967142/references?page=2